Overview
Updated 14 Jul 2026
Kenneth C. Anderson, MD, is Kraft Family Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute, Boston, MA. The public record shows 3,069 publications with 169,407 citations (h-index 199), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 17 companies, 6 NIH-funded awards (1991–2025).
- Most recent indexed publication: 2026 · Blood cancer journal
- Top research focus: Multiple Myeloma Research and Treatments
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 17 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 59 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 1,119.
Clinical & industrytrials, payments and federal funding
Public positionssourced statements on record
- As ASH President
issued public statement opposing the Administration's proposed cuts to NIH funding
2017verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hematology.org ↗
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
Sponsor: Biotest Pharmaceuticals Corporation
InvestigatorPhase 1/PHASE2CompletedNCT01638936 - Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Sponsor: Biotest Pharmaceuticals Corporation
InvestigatorPhase 1/PHASE2CompletedNCT01001442 - Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Sponsor: Biotest Pharmaceuticals Corporation
InvestigatorPhase 1CompletedNCT00723359
Industry payments
Updated 14 Jul 2026
17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Genentech, Inc.Program year20253 payments$11,400openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year20251 payment
- PFIZER INC.Program year20251 payment
NIH funding
Updated 14 Jul 2026
6 NIH research awards on record, funded 1991–2025 per NIH RePORTER. The latest:
- Project 3: Defining the biologic role and therapeutic implications of lncRNA in multiple myeloma
Dana-Farber Cancer Inst
FY2025$259,300P01CA155258 - Project 3: Defining the biologic role and therapeutic implications of lncRNA in multiple myeloma
Dana-Farber Cancer Inst
FY2024$240,658P01CA155258
Congress activity
Updated 14 Jul 2026
271 congress contributions (2000–2025) across AACR, ASCO, ASH, ESMO per OpenAlex. The most recent:
- Abstract 2978: PSMD6 is a promising therapeutic target in multiple myeloma
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Most-cited worksby citation count (OpenAlex)
- 01
- 02
- 03BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc2,849 citations2011
- 04A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma2,642 citations2003
- 05International uniform response criteria for multiple myeloma2,642 citations2006
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
450 Brookline Avenue, Boston, MA 02215
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
- MD
Johns Hopkins University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Residency
Internal Medicine, Johns Hopkins Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Fellowship
Medical Oncology/Hematology, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - BA
Biology, Boston University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
Secondary affiliationsappointments beyond the home institution
- Vice Chair
Joint Program in Transfusion Medicine, Harvard Medical School
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗ - Member
Dana-Farber/Harvard Cancer Center Lymphoma and Myeloma Program
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dfhcc.harvard.edu ↗
Media & interviewspress, podcasts and appearances
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- Interview
Journal of Community and Supportive Oncology (JCSO) podcast "Blood & Cancer"
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →jcsopodcast.libsyn.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/kenneth-anderson-md-335f8724
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/ken-anderson-87a69a188
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by otherswhere others cite or feature them
- LinkedIn
linkedin.com/posts/dana-farber-cancer-institute_congratulations-to-dr-kenneth-anderson-activity-6212280124201529344-hBAq
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Other
emjreviews.com/hematology/podcasts/hema-now-personalised-medicine-and-immunotherapy-in-multiple-myeloma
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emjreviews.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Tuhina Neogi, MD
Boston University
- 641
- publications
- 84
- h-index
- 2
- trials
Wilson Colucci, MD
Boston University
- 442
- publications
- 107
- h-index
- 2
- trials
William Boden, MD
Boston University
- 629
- publications
- 78
- h-index
- 3
- trials
Naomi Hamburg, MD
Boston University
- 368
- publications
- 76
- h-index
- 9
- trials